Anebulo Pharmaceuticals (FRA:214) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Anebulo Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2024 was €-1.38 Mil. Anebulo Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Anebulo Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Anebulo Pharmaceuticals's current FCF Yield % is -15.79%.

The historical rank and industry rank for Anebulo Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:214's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.2
* Ranked among companies with meaningful FCF Margin % only.

Anebulo Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Anebulo Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals FCF Margin % Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Anebulo Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Anebulo Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's FCF Margin % falls into.

Anebulo Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Anebulo Pharmaceuticals's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-8.937	/	0
	=	%

Anebulo Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.377	/	0
	=	%

Anebulo Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines